FDA Approves Subcutaneous Sarclisa Escena and Halts Real-Time Release of Rejection Letters

The U.S. Food and Drug Administration has approved Sanofi’s Sarclisa Escena as the first anticancer treatment administered via an on-body injector, offering a new delivery method for multiple myeloma patients. In a separate regulatory move, the agency has paused the real-time public release of complete response letters following a legal challenge concerning the protection of confidential commercial data. These updates arrive alongside news of a major Phase III trial failure for AstraZeneca’s heart disease candidate Wainua, which resulted in a significant loss of market value for the company.

The FDA's approval of subcutaneous Sarclisa Escena extends to all indications currently held by the drug’s intravenous version, making it a versatile option for multiple myeloma treatment. This approval is notable for introducing the CirCLIQ on-body injector to the U.S. oncology market, providing a delivery system that offers shorter administration times and fewer reactions compared to traditional intravenous methods. The decision was backed by the Phase III Iraklia trial, which confirmed that the on-body injector format maintains non-inferior efficacy and comparable pharmacokinetics to the original formulation.

Beyond product approvals, the FDA has temporarily suspended its practice of publishing complete response letters (CRLs) in response to a citizen petition filed by Covington and Burling. The petition, representing an anonymous pharmaceutical firm, contends that the real-time release of these rejection letters violates federal laws regarding confidential commercial information and fails to allow sponsors to review documents for redactions. While the agency moves toward a formal rulemaking process in late 2026 to clarify the commissioner's authority, recent rejections, such as a June denial for a Sobi gout treatment, have been kept from the public database.

Meanwhile, AstraZeneca faced a sharp 10 percent decline in share price following the failure of its Phase III Cardio-TTRansform trial for Wainua, a gene-silencing therapy developed with Ionis Pharmaceuticals. The trial failed to meet its primary endpoint of reducing cardiovascular deaths and events in patients with transthyretin-mediated amyloid cardiomyopathy over a 140-week period. Industry analysts attributed the failure to trial design issues, specifically the high number of patients already receiving stabilizer drugs at baseline, which made it difficult to isolate the therapeutic benefits of Wainua and raised concerns about the company's clinical strategy.